Encompass Health stock hits 52-week high at 126.52 USD

Encompass Health Corp (EHC) has reached a 52-week high of $126.52, reflecting a 36.17% stock increase over the past year, driven by robust Q2 2025 financial results that exceeded expectations with EPS of $1.40 and revenue of $1.46 billion. The company is actively expanding its footprint through a joint venture for a 50-bed rehabilitation hospital in Amarillo, Texas, and plans for a new facility in Haslet by 2027. Truist Securities recently raised its price target to $140 while maintaining a Buy rating, citing strong demand, despite the stock's RSI indicating overbought conditions.

Analysis

Encompass Health Corp. (EHC) has demonstrated significant momentum, reaching a 52-week high of $126.52, underpinned by strong operational performance and a clear growth trajectory. The company reported impressive Q2 2025 results, with EPS of $1.40 surpassing consensus estimates of $1.21, and revenue reaching $1.46 billion against a forecast of $1.43 billion. This financial strength is further supported by a year-over-year revenue growth of 11.8% and a robust gross profit margin of 42.4%. Investor confidence is bolstered by strategic expansion initiatives, including a joint venture for a 50-bed rehabilitation hospital in Texas and plans for another 50-bed facility by 2027, which are designed to capitalize on what management cites as "significant unmet sector demand." This positive outlook is echoed by Wall Street, evidenced by nine upward earnings revisions from analysts and a price target increase by Truist Securities to $140. However, the stock's 36.17% appreciation over the past year has pushed its RSI into overbought territory, signaling potential for short-term consolidation.

Key Decisions for Investors

• Investors should recognize the strong fundamental tailwinds, including consistent earnings beats and a defined expansion strategy, which support a long-term bullish case, with Truist's $140 price target suggesting further upside potential.
• Given the stock's recent 36.17% run-up and an RSI indicating overbought conditions, new capital deployment should be approached with caution, as the risk of a near-term pullback or consolidation has increased.
• Current shareholders could consider holding their positions based on the positive analyst sentiment and strong execution on growth initiatives, while monitoring technical indicators for signs of momentum exhaustion.